Opinion|Videos|January 5, 2026
Xanomeline/Trospium Mechanism of Action, Efficacy, and Safety
Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.
Advertisement
Episodes in this series
Panelists discuss how xanomeline/trospium chloride introduces a paradigm shift in schizophrenia therapy through selective muscarinic receptor activity, avoiding dopamine blockade.
Panelists discuss how phase 3 EMERGENT-2 and EMERGENT-3 trials demonstrated its efficacy in reducing psychotic symptoms with minimal metabolic or neurologic adverse effects.
Panelists discuss how this mechanism may redefine treatment options for patients who experience poor tolerability or limited response to existing dopamine-based therapies.
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
4
Who Recommends COVID-19 Vaccines Without ACIP?
5